MultiGeneAngio
Biologic
MultiGeneAngio is one of 76 biologic programs targeting Ischemia. It is currently in development.
2
Indications
2
Total Trials
1
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
159 competitors in Ischemia
#DrugCompanyPhaseTrials
1Adenocard
AstellasPhase 3
Isordil
AstraZenecaPhase 3
Osmitrol
BB. Braun Medical Inc.
Phase 3
Cardizem
BBausch Health Americas, Inc.
Phase 3
Flagyl
DDePuy Orthopaedics
Phase 3
Garamycin
SSchering-Plough
Phase 3
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Avlosulfon
AAlmirall, S.A.
Phase 3
Remodulin
United TherapeuticsPhase 3
Antioxidant
UUnity Health Toronto
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MultiGeneAngio. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Company
- MMultiGene Vascular Systems Ltd.